Among adults without CAD, the absolute risk for major bleeding with aspirin as primary prevention therapy exceeds the any absolute MI benefits for every level of atherosclerotic CVD risk, data from a meta-analysis show.
“We noted that adding aspirin would lead to higher major bleeding events among patients without CAD, which exceeds the ischemic benefits of aspirin,” Safi U. Khan, MD, MS, a cardiovascular disease fellow at Houston Methodist and DeBakey Heart and Vascular Center, told Healio. “Furthermore, if such patients are already on preventive statin therapy, adding